BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Market Cap	20.55B
Revenue (ttm)	1.19B
Net Income (ttm)	145.17M
Shares Out	422.10M
EPS (ttm)	0.34
PE Ratio	143.49
Forward PE	76.66
Dividend	0.10 (0.19%)
Ex-Dividend Date	Jul 4, 2024

Volume	7,401,548
Average Volume	8,079,872
Open	51.70
Previous Close	51.35
Day's Range	50.32 - 52.33
52-Week Range	22.82 - 52.50
Beta	0.31
RSI	72.36
Earnings Date	Aug 22, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,155
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 196.29 million, a decrease of -3.05%.